FAT4
FAT4 (Protocadherin Fat 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Colorectal cancer, Hepatocellular carcinoma and 5 more.
Overview
Cadherins are calcium-dependent cell adhesion proteins. FAT4 plays a role in the maintenance of planar cell polarity as well as in inhibition of YAP1-mediated neuroprogenitor cell proliferation and differentiation.
Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes literature 0.97, animal model 0.39, genetic association 0.36, somatic mutation 0.90). IntOGen calls it a driver in 37 cohorts (24 activating, 12 loss-of-function), covering Adrenocortical Carcinoma, Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Anal Squamous Cell Carcinoma, Basal Cell Carcinoma, Invasive Breast Carcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FAT4 (Protocadherin Fat 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Colorectal cancer, Hepatocellular carcinoma and 5 more.
- 1 · What it is
FAT4 (Protocadherin Fat 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Colorectal cancer, Hepatocellular carcinoma and 5 more.
- 2 · What goes wrong in cancer
Cadherins are calcium-dependent cell adhesion proteins. FAT4 plays a role in the maintenance of planar cell polarity as well as in inhibition of YAP1-mediated neuroprogenitor cell proliferation and differentiation.
- 3 · How drugs use it
No product in this corpus aims at FAT4 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:23109 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q6V0I7 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000196159 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: colorectal cancer 0.62, gastric cancer 0.56, oesophageal cancer 0.50, ovarian cancer 0.52, melanoma 0.60, non-Hodgkin lymphoma 0.52 (GraphQL API, CC0)); IntOGen FAT4 (driver in 37 cohorts (Act 24, LoF 12); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Cadherins are calcium-dependent cell adhesion proteins. FAT4 plays a role in the maintenance of planar cell polarity as well as in inhibition of YAP1-mediated neuroprogenitor cell proliferation and differentiation. Location: Membrane (UniProt). Locus 4q28.1 (HGNC).
- Prostate cancer: IntOGen driver in 4 cohorts (PRAD)
- Colorectal cancer: Open Targets association 0.62 with colorectal cancer (MONDO_0005575); IntOGen driver in 1 cohort (COADREAD)
- Hepatocellular carcinoma: IntOGen driver in 3 cohorts (HCC)
- Breast cancer: Open Targets association 0.60 with breast cancer (MONDO_0007254); IntOGen driver in 2 cohorts (BRCA)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.56 with gastric cancer (MONDO_0001056); IntOGen driver in 2 cohorts (STAD, STOMACH)
- Oesophageal cancer: Open Targets association 0.50 with oesophageal cancer (MONDO_0007576); IntOGen driver in 2 cohorts (ESCA)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 24 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 12 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FAT4" OR ABSTRACT:"FAT4" OR TITLE:"FAT atypical cadherin 4" OR ABSTRACT:"FAT atypical cadherin 4" OR TITLE:"Protocadherin Fat 4" OR ABSTRACT:"Protocadherin Fat 4" OR TITLE:"CDHF14" OR ABSTRACT:"CDHF14" OR TITLE:"FAT-J" OR ABSTRACT:"FAT-J" OR TITLE:"CDHR11" OR ABSTRACT:"CDHR11") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FAT4, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNCOR2
Shares Mesothelioma, Skin cancer (all types), Oesophageal cancer, Hepatocellular carcinoma.
- TargetNCOR1
Shares Mesothelioma, Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetBAP1
Shares Mesothelioma, Oesophageal cancer, Hepatocellular carcinoma, Breast cancer (all types).
- TargetPBRM1
Shares Mesothelioma, Skin cancer (all types), Oesophageal cancer, IntOGen.
- TargetLATS2
Shares Mesothelioma, Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetNFKB2
Shares Mesothelioma, Skin cancer (all types), IntOGen, Open Targets Platform.
- TargetSETDB1
Shares Mesothelioma, Hepatocellular carcinoma, Breast cancer (all types), IntOGen.
- TargetNIN
Shares Mesothelioma, IntOGen, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.